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This research was motivated by our goal to design an efficient clinical trial to compare two doses 
of docosahexaenoic acid supplementation for reducing the rate of earliest preterm births and/or 
preterm births. Dichotomizing continuous gestational age data using a classic binomial 
distribution will result in a loss of information and reduced power. A distributional approach is 
an improved strategy to retain statistical power from the continuous distribution. However, 
appropriate distributions that fit the data properly, particularly in the tails, must be chosen, 
especially when the data are skewed. A recent study proposed a skew-normal method. We 
propose a three-component normal mixture model and introduce separate treatment effects at 
different components of gestational age. We evaluate operating characteristics of mixture model, 
beta-binomial model, and skew-normal model through simulation. We also apply these three 
methods to data from two completed clinical trials from the USA and Australia. Finite mixture 
models are shown to have favorable properties in preterm births analysis but minimal benefit for 
earliest preterm births analysis. Normal models on log transformed data have the largest bias. 
Therefore we recommend finite mixture model for preterm births study.  Either finite mixture 
model or beta-binomial model is acceptable for earliest preterm births study. 
 






In many circumstances, clinical researchers are interested in studying categorized outcomes 
using cutoff points despite continuous measurements being collected. It has been widely 
accepted that dichotomizing continuous data prior to analysis results in a loss of information and 
reduced power [1, 3, 10]. A distributional approach can be used to dichotomize continuous data 
while retaining the statistical power from the continuous distribution [10]. Peacock et al. [10] 
described the use of the distributional method and showed the good performance of this 
parametric approach under standard normal distributional assumptions.  Sauzet et al. [12] further 
discussed the distributional approach when the outcome is skewed and proposed a skew-normal 
distributional method for dichotomization. They used a logarithm transformation to normalize 
negatively skewed gestational age data and then applied the skew-normal distributional method 
under the Frequentist framework. They acknowledged that no satisfactory transformation is 
available for gestational age data [12].  Mixture models with different components might be a 
better choice for skewed outcomes such as gestational age, because they allow for greater 
flexibility in modeling heterogeneous populations [9], which largely explains the skewness of 
gestational age data.  
Our research was motivated by our goal to design an efficient clinical trial to compare two 
doses of docosahexaenoic acid (DHA) supplementation for reducing the rate of earliest preterm 
births (ePTB, gestation age<34 weeks) and/or preterm births (PTB, gestational age<37 weeks). 
Both endpoints have been evaluated in past studies [7]. The United States currently has a PTB 
rate of 11.4% [6] and babies born preterm are at increased risk of immediate life-threatening 
health problems, as well as long-term complications and developmental delays [4]. Among 





complications. Although the overall PTB rates have decreased over time, the ePTB rates in the 
U.S. have decreased little since 1990 and the overall ePTB rates in the US for 2012 were 3.4% 
[8]. These births impact overall infant mortality the most and result in much higher hospital costs 
than uncomplicated births [11]. Docosahexaenoic acid (DHA) supplementation potentially 
provides a high yield, low risk provocative strategy to reduce early preterm delivery [4]. We 
designed a Phase III clinical trial (randomized to low or high dose DHA, double-blind) to 
examine the efficacy of 1000 mg/day DHA supplementation to reduce the probability of earliest 
preterm births and/or preterm births compared to 200 mg/day, an amount recommended by the 
FAO/WHO for pregnant and lactating women and currently in many prenatal supplements. Our 
goal was to identify a powerful design that would provide an efficient estimate of the treatment 
effect. 
Gestational age (GA) data will be measured in completed weeks/days and collected in a 
continuous form. The two clinically important endpoints of interest are: ePTB (GA<34 weeks) 
and PTB (GA<37 weeks). The traditional analysis approach is to dichotomize the continuous 
gestational age data using these cutoff points and to compare the probabilities of binary 
outcomes, using a chi-square test for example. Distributional methods compare the proportions 
below the cutoff points in continuous distributions [4, 10]. Sauzet et al. [12] proposed a skew-
normal method and used normal distribution on the logarithmic transformed data. We propose a 
three-component normal mixture model and apply the distributional approach directly. The aim 
of this study is to compare these three statistical methods under a fixed Bayesian design 
framework for a very rare endpoint (ePTB) and a less rare endpoint (PTB).  
The remainder of this article is arranged as follows. In section 2, we describe three statistical 





provide the simulation details under a fixed Bayesian clinical trial design framework and 
compare these three statistical methods in several realistic outcome scenarios. In section 4, we 
apply these three methods to data from two completed clinical trials, one in the USA and one in 
Australia. The results from the real data analysis are examined and compared. In section 5, we 
discuss the observations from the simulations and real data analysis and further investigate the 
rationale of these observations. In section 6, we discuss the limitations of this study. In section 7, 
we draw conclusions from our analysis and give suggestions to future studies. 
2. STATISTICAL MODELS 
Let 𝒀𝑗  = (𝑌𝑗1,…, 𝑌𝑗𝑛𝑗) denote the continuous data of gestational age, where j denotes the 
treatment group assignment (j=c for participants in the control group and j=t for participants in 
the treatment group) and 𝑛𝑗  denotes the sample size in the j
th treatment group in a two-armed 
randomized clinical trial design. Let 𝑝𝑗 denote the probability of ePTB or PTB in the j
th treatment 
group. 
The first method considered involves dichotomizing the data prior to modeling. We propose 
a beta-binomial model to simplify a Bayesian inference of 𝑃(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎), denoting the 
posterior probability that control has a higher ePTB/PTB rate than treatment. Because the 
endpoints considered are rare, using a uniform prior or a beta (1,1) prior might induce non-
negligible bias. We therefore assume a very weak prior of 𝑝𝑗 as beta (0.01, 0.01). Furthermore, 
the posterior mode is close to a classical Frequentist approach (i.e., Maximum Likelihood 
Estimator). Let 𝑋𝑗 = ∑ 𝐼(𝑌𝑗𝑖 < 34 𝑜𝑟 37), where 𝐼(𝑥 < 𝑦) = {
1, 𝑥 < 𝑦
0, 𝑥 ≥ 𝑦
𝑛𝑗
𝑖=1  and 𝑛𝑗  is the sample 





distribution: 𝑋𝑗|𝑝𝑗~𝑏𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑛𝑗 , 𝑝𝑗). The posterior distribution of 𝑝𝑗|𝑋𝑗~ 𝑏𝑒𝑡𝑎 (𝑋𝑗 + 0.01, 𝑛𝑗 −
𝑋𝑗 + 0.01  ).  
The second method considered is a distributional approach, where we will apply the 
transformation recommended by Sauzet et al. [12]. First we take a logarithmic transformation of 
(45-GA) to normalize the data because we expect GA in weeks to be <45 and is negatively 




2). Since the 
logarithmic transformation is a continuous and monotonic transformation, this does not affect the 
proportion below a cut-point [12]. The proportions of GA below 34 and 37 are translated into the 
proportions greater than log(45-34) =2.3979 and log(45-37) =2.0794 in the normal distribution 
𝑁(𝜇𝑗, 𝜎𝑗
2).  We use non-informative conjugate priors for the parameters in the normal 
distribution: 𝑁(0, 1002) for 𝜇𝑗 and Gamma (0.001, 0.001) for 
1
𝜎𝑗
2. The posterior probability of 
ePTB or PTB (𝑝𝑗|𝒁𝑗) is calculated as 𝑝𝑗|𝒁𝑗 = ∫ ɸ(𝑦|𝜇𝑗 , 𝜎𝑗
2)
∞
2.3979 𝑜𝑟 2.0794 
 dy, where 
ɸ(𝑦|𝜇𝑗 , 𝜎𝑗







∑ (𝑍𝑗𝑖 − 𝑍?̅?)
2𝑛𝑗









The third method considered is another distributional approach using the finite normal 
mixture model. Peacock et al. [10] showed the good performance of the parametric approach 
under traditional normal distributions. We extend this approach here and propose a finite mixture 
normal model to allow for population heterogeneity. In this method, we apply a three-component 
normal mixture model derived from the North Carolina Detailed Birth Record (NCDBR) 
database with 336,129 observations in the final analysis: a three-component mixture of N(39.59, 





model show these estimates are reliable in this registry data. The first component has a mean of 
39.59 (39.58, 39.61), and variance of 0.96 (0.95, 0.97). The second component has a mean of 
38.26 (38.20, 38.32) and variance of 2.48 (2.42, 2.54). The third component has a mean of 33.29 
(33.07, 33.51) and variance of 13.23 (12.78, 13.67) [14]. Although we used fixed parameter 
estimates from a U.S. registry data, this model has unprecedented advantages in gestational age 
data analysis or clinical trial design, even for a different population. Firstly, the parameter 
estimates are derived from a huge registry data thus is representative and has generalizablility.  
Secondly, a three-component mixture normal model has its own flexibility to model similar but 
not exactly the same gestational age data from a different population by allowing various 
component weights. Thirdly, the three components are realistic and interpretable. The three 
components represent low, medium, and high-risk groups for PTB separately. We assume a unity 
prior for ∆𝒋 (j=c,t), the mixture weights in the j
th treatment group, and the three-component 
normal mixture model can be written as:  𝑓(𝑌𝑗𝑖|∆𝒋) =∆1𝑗ɸ(𝑌𝑗𝑖|39.59, 0.96) +
∆2𝑗ɸ(𝑌𝑗𝑖|38.26, 2.48) +∆3𝑗ɸ(𝑌𝑗𝑖|33.29, 13.23), where ɸ (𝑦|𝜇, 𝜎
2) denotes the density of y in a 
normal distribution with mean 𝜇 and variance 𝜎2, and  ∆1𝑗, ∆2𝑗 , 𝑎𝑛𝑑 ∆3𝑗  denote the mixture 
weights in the jth treatment group, with ∆1𝑗 +  ∆2𝑗 + ∆3𝑗= 1. In this method, the posterior 
probability of ePTB or PTB (𝑝𝑗|𝒀𝑗) is calculated as: 𝑝𝑗|𝒀𝑗 = ∫ 𝑓(𝑦|∆𝒋)
34 𝑜𝑟 37
−∞
 dy. A more 
general approach would be to let each component’s mean and variance be freely modeled. 
However, we found our approach was flexible and appropriate for our focus on the lower tail. 
More flexible models allowing components’ means and variances to vary are considered for 
future analysis, especially when more data are available.  





A previous Phase III trial comparing 600 mg DHA per day and placebo, Kansas University 
DHA Outcome Study [KUDOS], found an 85% reduction in ePTB with DHA supplementation 
[2]. Another Australian trial, DHA to Optimize Mother Infant Outcome [DOMInO] trial, which 
compared 800 mg DHA per day and placebo, found a 50% reduction in ePTB with DHA 
supplementation [7]. In both trials, ePTB was a secondary outcome [2, 7]. The primary aim of 
the current proposed Phase III randomized, double-blind trial is to test the hypothesis that ePTB 
and/or PTB is reduced by 1000 mg of DHA per day compared to 200 mg DHA per day. We 
performed a simulation study based on realistic response scenarios to investigate the operating 
characteristics of this fixed Bayesian clinical trial design. 
3.1 Simulation Methods 
We simulated gestational age data using different true values of mixture weights (∆𝟎) with 
resulting probabilities of ePTB or PTB close to probability scenarios we observed from our 
clinical trials [2]. In the beta-binomial model, we used simulation to generate the posterior 
distribution of 𝑝𝑗|𝑋𝑗~ 𝑏𝑒𝑡𝑎 (𝑋𝑗 + 0.01, 𝑛 − 𝑋𝑗 + 0.01  ) for both treatment and control groups 
and calculated the probability of 𝑝𝑐|𝑋𝑐 > 𝑝𝑡|𝑋𝑡. In the finite mixture model, we used Markov 
Chain Monte Carlo (MCMC) to generate posterior distributions of ∆𝒋 and the posterior 
probability 𝑝𝑗|𝒀𝑗  was calculated as: 𝑝𝑗|𝒀𝑗 = ∫ 𝑓(𝑦|∆𝒋)
34 𝑜𝑟 37
−∞
 dy. In the logarithmic 
transformation method, we used Gibbs sampling to generate posterior distributions of 
𝜇𝑗𝑝 𝑎𝑛𝑑 𝜎𝑗𝑝
2 . The posterior probability 𝑝𝑗|𝒁𝑗  was calculated as ∫ ɸ(𝑦|𝜇𝑗𝑝, 𝜎𝑗𝑝
2 )
∞
2.3979 𝑜𝑟 2.0794 
 dy. 
If Pr(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿, we counted this as a trial success. The posterior mean of 𝑝𝑗|𝑑𝑎𝑡𝑎, 
𝑝?̂? = E(𝑝𝑗|𝑑𝑎𝑡𝑎), was saved for each simulation in each of the three models. In all models, the 










  for each treatment 
group, where S was the number of simulations. The MSE of 𝐸(𝑝?̂?) was calculated as 𝑏𝑖𝑎𝑠
2 +
 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = (𝐸(𝑝?̂?)  − 𝑃𝑗,0)
2 + 𝑉𝑗, with 𝑃𝑗,0 denoting the true probability of ePTB or 
PTB in the jth treatment group.  
To mimic situations for ePTB in future trials, we simulated 5 scenarios with varying 
treatment effects: no effect (3 vs. 3%, difference=0), very small (3 vs. 2%, difference=1%), small 
(3 vs. 1%, difference=2%), medium (3 vs. 0.5%, difference=2.5%) and large (4 vs. 1%, 
difference=3%) based on our previous clinical trial results [2]. To mimic situations for PTB in 
future trials, we simulated another 5 scenarios: no treatment effect (8 vs. 8%, difference=0), very 
small (8 vs. 7%, difference=1%), small (8 vs. 6%, difference=2%), medium (8 vs. 5%, 
difference=3%) and large (8 vs. 4%, difference=4%) based on results from our previous clinical 
trial [2]. In the null scenarios where the treatment effect was 0, we identified the 𝛿 values which 
made the average success rate across simulations approximately equal to 0.05, P(Pr(𝑝𝑐 >
𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿)  ≈ 0.05. 𝛿 values can vary in different statistical methods. This ensured the type 
I error rate was about 5%. In other scenarios, P(Pr(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿) was used to calculate 
the power of the tests. 
We compared the simulated trial operating characteristics, (bias, power and MSE) across the 
three models for both ePTB and PTB. These were based upon 1000 simulations and 600 subjects 
in each group because our designed trial has a sample size around 1200.  The 𝛿 value was 0.95 
for both ePTB and PTB simulations, in the beta-binomial model and the finite mixture model. In 
the logarithmic transformation model, 𝛿 was 0.999 for ePTB simulations and 0.997 for PTB 
simulations. The 𝛿 value was variable in simulation studies to ensure the Type I error rate is 





controlling for Type I error. Using the same 𝛿 value for log-transformed model will boost the 
Type I error for this method. All methods were implemented in R 3.1.1 and Openbugs. 
3.2 Simulation Results 
In the simulation study of probability of ePTB (<34 weeks), the beta-binomial model had 
lower bias compared to the finite mixture model and the logarithmic transformation model in all 
scenarios. The MSE in the finite mixture model was consistently lower than in the beta-binomial 
model and logarithmic transformation model in the control group and slightly higher than in the 
beta-binomial model in the last three scenarios in the treatment group (Table 1).  Figure 1 shows 
the comparisons of bias, variance, MSE and power across the three models. In the null scenario, 
the type I error rate was 0.048 in the beta-binomial model, 0.054 in the finite mixture normal 
model, and 0.053 in the logarithmic transformation model (Table 1). The power for the finite 
mixture model was slightly higher than the beta-binomial model in other scenarios, but the 
difference was small (Figure1). The logarithmic transformation model had the largest bias and 
lowest power (Table 1). 
In the simulation study of probability of PTB (<37 weeks), the beta-binomial model 
continued to have lower bias compared to the finite mixture normal model and the logarithmic 
transformation model. The difference in MSE between the finite normal mixture model and the 
beta-binomial model was larger than that in the ePTB simulations (Table 1 and Table 2). The 
logarithmic transformation model again had the largest bias and largest MSE (Table 2).  In the 
null treatment effect scenario, the type I error rate was 0.054 in the beta-binomial model, 0.05 in 
the finite mixture normal model, and 0.051 in the logarithmic transformation model (Table 2). 
The power for the finite mixture model was higher than the beta-binomial model in small to large 





(Table 2). Figure 2 shows the comparisons of bias, variance, MSE and power across the three 
models. 
These simulation results demonstrated that although the bias from the finite mixture method 
was larger than that from the pre-dichotomizing method, the parameter estimates from the finite 
mixture method had desirable properties such lower variance. In ePTB simulation, the finite 
mixture model did not appear to be more desirable than the beta-binomial model. However, the 
finite mixture model improved the power and MSE in PTB analysis. The logarithmic 
transformation method has the largest bias and highest MSE. In a word, the logarithmic 
transformation model appeared to be inferior to the finite mixture model. The bias in the log-
transformed model is not driven by 𝛿 value but the fact that this model cannot model the 
distribution of gestation age very well. 
4. APPLICATION TO REAL DATA 
To illustrate the use of the three models in real data, we reanalyzed the gestational age data 
from an Australia based clinical trial and a USA based clinical trial.  
4.1 DOMInO Trial 
The DOMInO trial was a double-blind, multicenter, randomized controlled trial conducted 
in five Australian maternity hospitals. The trial included 2399 women who were less than 21 
weeks' gestation with singleton pregnancies and who were recruited between October 31, 2005, 
and January 11, 2008 [7]. This study compared fish oil capsules (providing 800 mg/d of DHA) or 
matched vegetable oil capsules without DHA. Gestational age data were available for 2367 
(1183 in control and 1184 in treatment) participants in this study. 
We looked at the posterior summary statistics of the posterior component probabilities in the 





group, the posterior probability of the first component (low risk of PTB) increased from 0.783 to 
0.813 and the posterior probability of the third component (high risk of PTB) decreased from 
0.04 to 0.022. The posterior probability of the second component decreased from 0.177 to 0.165. 
Convergence diagnostics were checked to ensure the convergence of posterior samples. 
In Table 4, we show the calculated and estimated probability of ePTB and PTB and the 
standard deviation of the estimated probabilities. In this analysis, we found the benefits of the 
finite mixture model were not clear in ePTB but the standard deviation was slightly smaller in 
the finite mixture model in PTB analysis. The estimated proportions for the log transformation 
model are quite different to the raw data (Table 4). Since we don’t know the true parameter 
value, we won’t be able to calculate bias and MSE. 
4.2 KUDOS Trial 
KUDOS was a Phase III, randomized, double-blind, placebo-controlled clinical trial 
involving 299 women [2].  This study compared participants in the placebo group (𝑛1 = 145) 
and participants who received 600 mg/day DHA (𝑛2 = 154) in the second and third trimester 
during pregnancy from 2001 to 2006 in the University of Kansas Hospital [2].  
The posterior summary statistics of the mixture weights were summarized in Table 3. 
Compared to the DOMInO trial, the difference in the three component probabilities between 
treatment and control groups was much larger (Table 3). The mixture weight of the third 
component (high risk of PTB) decreased dramatically from 0.089 in the control group to 0.029 in 
the intervention group. The weight of the second component increased from 0.073 to 0.196. Both 
indicate the improvement in the intervention group. Convergence diagnostics were checked to 





In Table 4, we show the calculated and estimated probability of ePTB and PTB and the 
standard deviation of the estimated probabilities. Again in this analysis, we found the advantages 
of the finite mixture model compared to beta-binomial model were not very clear for ePTB but 
the standard deviation was smaller in the finite mixture model for PTB. Both the DOMInO and 
KUDOS data were consistent with the simulation studies and showed that the benefits of the 
finite mixture model were questionable for ePTB but might exist in PTB analysis. The 
logarithmic transformation model produced quite different results compared to the other two 
models, which may be due to the bias in this method observed in the simulation study.  
5. DISCUSSION 
We aimed to investigate the properties of pre-dichotomizing and distributional approaches 
using a three-component normal mixture model and a logarithmic transformation model. The 
three-component normal mixture model has been demonstrated to be identifiable and superior to 
two-component mixture models while avoiding the poor mixing in models with four or more 
components [14]. The Bayesian framework provides us with a convenient tool to compare 
distributional approaches and the pre-dichotomizing method.  
In the simulation study, we used a weak beta prior for the beta-binomial model to ensure the 
bias was negligible and the estimates were close to the Frequentist approach. As a result, the bias 
from the finite mixture model was greater than that from the beta-binomial model. However, the 
finite mixture model had lower variance in all scenarios (Figure 1 and Figure 2). In the ePTB 
analysis where the endpoint was very rare, the power of the finite mixture model was only 
slightly higher than the beta-binomial model and the benefits of the finite mixture model were 
relatively small. The benefits of the finite mixture model were more apparent in the PTB analysis 





finite mixture model compared with the other methods. The power in the finite mixture model 
was higher except in the very small difference scenario, where it is slightly lower than the beta-
binomial model. The logarithmic transformation model had the largest bias and MSE. 
In real data analysis, both DOMInO and KUDOS trial data demonstrated that the finite 
mixture model was not superior in ePTB analysis. The finite mixture model had lower standard 
deviation compared to the beta-binomial model for PTB in both datasets. The logarithmic 
transformation model produced quite different results in both analyses. These findings confirmed 
previous findings that the logarithmic transformation was not satisfactory for GA data [12].  
Further investigating the three-component mixture model facilitates understanding of our 
observations in the simulation study and real data analysis. The three mixture components are: 
N(39.59, 0.96), N(38.26, 2.48), and N(33.29, 13.23). The mixture weights are about 70-80% for 
the first component, 10-20% for the second component, and less than 10% for the third 
component. The three components have different means and standard deviations 
(heteroscedastic). Therefore it is not straightforward to describe the exhibition of the mixture 
distribution. However, we can still speculate the mixture exhibition from the three mixture 
components and the mixture weights. The first two components have close means and different 
standard deviations. Distribution mixing these two will display high kurtosis with a sharper peak 
and heavier tails than a single distribution [5]. The third component is sufficiently separated from 
the first two components. The difference in the means between the second and third components 
is greater than two times the standard deviation of the second component. Mixing of these two 
could form a bimodal distribution [13]. Since the mixture weights of the first two components 
are dominant and the standard deviation of the third component is large, the exhibition could 





Based on the exploration of the finite mixture model, we can obtain an intuitive explanation 
of our observations. In the ePTB analysis we used GA<34 as a cutoff. Given the exhibition of the 
mixture model, the area below 34 was mainly captured by the third component of the 
distribution. In the PTB analysis we used GA<37 as a cutoff and the area below 37 was 
comprised of the second and the third components, while the influence of the first component 
was trivial. Therefore in the ePTB analysis, the finite mixture model did not appear to be much 
better than the beta-binomial model in terms of power because most of the information we 
needed to make inference on the probability of ePTB was captured by one mode in a bimodal 
exhibition. In the PTB analysis, the information to make inference on the probability of PTB was 
captured by two components and the finite mixture model captured the information from the 
trend of the two components and retained the power from the continuous distribution. Gestation 
age analysis is a single example in real life where we care about dichotomized outcomes while 
continuous data are collected. This study showed the cutoff value and the exhibition of the 
distribution were important to understand the mechanism of gaining power from a continuous 
distribution.  This conclusion can be generalized to other studies in which the outcome is 
dichotomized while data are collected in a continuous form. 
6. LIMITATIONS 
There are a few assumptions we have made to pursue this study. Firstly, we used the 
parameter estimates of the normal components from the North Carolina Detailed Birth Record 
(NCDBR) database and applied them to different populations. We assumed these component 
parameters were valid in different populations and they appeared to be fine in this study as the 
estimated probabilities are quite close to the true data. Although the finite mixture model has 





formation of the mixture model could change in other populations if the population is extremely 
different. Secondly, we assumed there was no measurement error in the gestational age data. 
Gestational age data were obtained from medical records but we do not have a technique to test 
the measurement error in the current study. If the measurement error was large, it could blur the 
boundary of ePTB and PTB.  
7. CONCLUSION 
In studies where endpoints are collected as continuous variables but clinicians are interested 
in studying dichotomized outcomes, a pre-dichotomizing or distributional approach could be 
used for analysis. In general, a distributional approach that fits the data well retains information 
and power from the continuous distribution, while a dichotomizing method is close to the 
traditional Frequentist approach and may result in less bias. The benefits of a distributional 
method depend on model fit, cutoff values, and the exhibition of the continuous distribution. 
Meticulous investigation of the distributions is necessary, especially in rare endpoint analysis 
where retaining statistical power is more important. In our clinical trial designs for gestational 
age data, we recommend the finite mixture normal model if the endpoint is PTB (<37 weeks) 
since this is a more powerful design and beta-binomial model if the endpoint is ePTB (<34 
weeks) since the power from these two designs are close and beta-binomial model has less bias. 
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Table 1: Simulated Trial Operating Characteristics for Probability of ePTB (GA<34 weeks) 
 
Scenarios  Bias MSE×105 Power 
 Method Control Tx Control Tx  
No 
difference  
(3 vs. 3%) 
Beta-Binomial Model .00009 .00006 4.62 4.78 .048 
Finite Mixture Model .00144 .00119 4.02 4.17 .054 
Logarithmic Transformation Model .01983 .01954 58.56 59.21 .053 
Very Small 
(3 vs. 2%) 
Beta-Binomial Model .00037 .00005 4.53 3.39 .275 
Finite Mixture Model .00099 .00123 4.08 3.13 .286 
Logarithmic Transformation Model .02051 .01493 53.46 28.14 .164 
Small 
(3 vs. 1%) 
Beta-Binomial Model .00034 .00028 5.03 1.69 .845 
Finite Mixture Model .00160 .00171 4.63 1.82 .857 
Logarithmic Transformation Model .02051 .00713 53.46 7.19 .58 
Medium 
(3 vs. 0.5%) 
Beta-Binomial Model .00043 .00004 4.69 0.89 .983 
Finite Mixture Model .00156 .00160 4.20 1.00 .985 
Logarithmic Transformation Model .01983 .00347 58.58 2.51 .794 
Large 
(4 vs. 1%) 
Beta-Binomial Model .00010 .00010 6.57 1.51 .984 
Finite Mixture Model .00120 .00143 5.47 1.55 .989 
Logarithmic Transformation Model .02554 .00667 89.75 10.72 .863 
 Power: average success rate across simulations, P(Pr(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿), 𝛿 = 0.95 for Beta-binomial and finite mixture model, 
















Table 2: Simulated Trial Operating Characteristics for Probability of PTB (GA<37 weeks) 
 
Scenarios  Bias MSE×105 Power 
 Method Control Tx Control Tx  
No 
difference  
(8 vs. 8%) 
Beta-Binomial Model .00056 .00003 12.3 11.6 .054 
Finite Mixture Model .00235 .00224 10.3 10.1 .05 
Logarithmic Transformation Model .03265 .03286 175 178 .051 
Very Small 
(8 vs. 7%) 
Beta-Binomial Model .00002 .00016 12.6 11.4 .164 
Finite Mixture Model .00184 .00239 10.4 9.59 .163 
Logarithmic Transformation Model .03266 .02859 175 151 .129 
Small 
(8 vs. 6%) 
Beta-Binomial Model .00070 .00024 12.1 9.05 .378 
Finite Mixture Model .00149 .00218 9.90 7.47 .418 
Logarithmic Transformation Model .03266 .02134 175 98 .343 
Medium 
(8 vs. 5%) 
Beta-Binomial Model .00051 .00006 12.2 7.86 .693 
Finite Mixture Model .00224 .00225 10.8 6.33 .768 
Logarithmic Transformation Model .03266 .01439 175 56 .687 
Large 
(8 vs. 4%) 
Beta-Binomial Model .00025 .00008 12.9 6.64 .908 
Finite Mixture Model .00224 .00246 11.5 4.98 .952 
Logarithmic Transformation Model .03223 .00789 157 19 .94 
Power: average success rate across simulations, P(Pr(𝑝𝑐 > 𝑝𝑡|𝑑𝑎𝑡𝑎) > 𝛿), 𝛿 = 0.95 for Beta-binomial and finite mixture model, 𝛿 =

















Table 3: Posterior summary statistics for mixture weights in finite mixture model in DOMInO and KUDOS trial (10000 simulations) 
 
  Control  Treatment 
  mean std  mean std 
DOMInO ∆1 .783 .022  .813 .021 
∆2 .177 .023  .165 .021 
∆3 .040 .007  .022 .006 
KUDOS ∆1 .838 .048  .775 .060 
∆2 .073 .048  .196 .063 
∆3 .089 .027  .029 .018 
 
∆1: posterior probability of component 1, N(39.59, 0.96) 
∆2: posterior probability of component 2, N(38.26, 2.48) 























Table 4: DOMIinO and KUDOS Data analysis: calculated and estimated probability of GA less than certain cutoff, standard deviation, 




Data Beta-Binomial Model Finite Mixture Model Log-Transformation Model 
   Pc0 Pt0 Pc Pt SDc SDt Pc Pt SDc SDt Pc Pt SDc SDt 
DOMInO <34 
wks 
.023 .011 .023 .011 .004 .003 .024 .013 .004 .003 .009 .004 .001 .001 
<37 
wks 
.072 .055 .072 .055 .008 .007 .075 .057 .007 .006 .099 .068 .007 .007 
KUDOS <34 
wks 
.048 .007 .048 .007 .018 .007 .052 .018 .016 .011 .016 .004 .006 .002 
<37 
wks 
.09 .065 .09 .065 .024 .02 .094 .069 .022 .017 .136 .069 .023 .016 
 
 
Outcome: probability of GA less than a certain amount of time 
Pc0: the calculated probability in the data in control group 
Pt0: the calculated probability in the data in treatment group 
Pc:  the estimated probability in the control group 
Pt: the estimated probability in the treatment group 
SDc: standard deviation in the control group 
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